Cann Group Secures Additional R&D Funding Advance

The latest update is out from Cann Group ( (AU:CAN) ).

Cann Group Limited has received a second advance of $315,552 from Radium Capital, providing early access to its expected R&D Tax Incentive for FY2025. This funding, along with a previous advance, totals $1,152,021 and will be repaid upon receipt of the R&D rebate or by 31 October 2025. This financial maneuver supports Cann Group’s ongoing R&D activities, potentially strengthening its position in the cannabis industry by ensuring continuous innovation and product development.

More about Cann Group

Cann Group Limited is a company focused on enhancing patients’ lives by developing, producing, and supplying innovative cannabis medicines. It operates research facilities and a large-scale cultivation and GMP manufacturing facility in Victoria, Australia. The company offers a range of dried flower and oil products, active pharmaceutical ingredients, and extracts to customers globally. Cann Group also owns Satipharm and its patent-protected capsule technology.

YTD Price Performance: -66.67%

Average Trading Volume: 1,935,771

Technical Sentiment Signal: Sell

Current Market Cap: A$8.27M

Find detailed analytics on CAN stock on TipRanks’ Stock Analysis page.